AUS Congressional Committee is launching an investigation into whether US Food and Drug Administration (FDA) was lenient in allowing Ranbaxy to sell new drugs in the US market when it was still investigating discrepancies at the Indian pharma major's manufacturing facility in India. The committee will also examine whether the USFDA took timely action against Ranbaxy.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/us-fda-role-ranbaxy-case-comes-under-scanner
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/economic-times-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/ranbaxy-pharmaceuticals
